PrintFriendly
Featured News
|
Monday, April 16, 2018  The company donated over 25 million international units (IU) of factor products used to treat hemophilia A and B. |
|
Wednesday, April 11, 2018  Val D. Bias spoke to the leaders of NHF’s 52-chapter networks at the NHF 2018 Chapter Leadership Seminar in San Francisco, California. |
|
Friday, March 30, 2018  2018 marks NHF’s 70th year as the bleeding disorders community’s chief advocate. |
|
Friday, March 30, 2018  Applications are now open! The selected KCS recipient will receive an award of $1,000 toward their tuition costs. |
|
Wednesday, March 28, 2018  Updated statement from Genentech on Hemlibra, March 28, 2018. |
|
Tuesday, March 27, 2018  The screening kit was developed for broad utility for both laboratories seeking a standardized inhibitor assay for clinical management and multi-center clinical studies of patients with hemophilia A |
|
Tuesday, March 27, 2018  NHF received information from Genentech’s Clinical Development Lead regarding reports of the death of patients utilizing Hemlibra (emicizumab). |
|
Monday, March 26, 2018  The activity will discuss recent advances in the understanding of inhibitors in patients with hemophilia A, including the risks associated with inhibitors as well as current and new approaches to management. |
|
Tuesday, March 20, 2018  Aptevo Therapeutics recently announced patient-reported data on individuals currently being treated with IXINITY®, the company’s recombinant factor IX product. |
|
Tuesday, March 20, 2018  CSL Behring Discontinues Production and Distribution of Monoclate-P® |